Maui Potpourri (2.13.2026) Dr. Jack Cush reviews the hot item takeaways from last week's RheumNow Live 2026. https://t.co/ieRhIVZb2D https://t.co/KaYtSnHUIL

RT @gibson_rheumPAC Given rising resistance, effective first-line regimens and adequate duration (14 days) are critical. PPI-based quadruple regimens remain highly effective when patients can adhere. #RNL26 https://t.co/rQps2rls8G

RT @gibson_rheumPAC Who should be tested? Test only if you plan to treat. Indications include: • Active or prior ulcers • MALT lymphoma • Gastric cancer • Chronic atrophic gastritis Avoid indiscriminate testing. #RNL26 atoid arthritis https://t.co/2KJluSAPNx

Genentech announced results of Phase III, MAJESTY OL study of obinutuzumab vs tacrolimus in 142 pts w/ primary membranous nephropathy & found signif more complete remissions at 2 yrs in obintuzumab Rx pts. Obintuzumab (Gazyva) if FDA approved for lupus nephritis. https://t.co/maJbvUCkBe

Screening study of lung US (LUS) vs HRCT in 73 RA pts (DAS28 3.47) Chest HRCT identified ILD in 29%. LUS identified ILD in 22% of patients. LUS sensitivity was 59%; specificity 94%. ROC. This study demonstrates the good diagnostic performance of LUS in RA- ILD detection https://t.co/E8avnbvUiw

Rotator cuff abnormalities are nearly universal after age 40, & incr w/ age; routine imaging should not guide Dz or Tx of atraumatic shoulder pain. Study of 602 having MRI (58yrs) RC abnormalities in 98.7%;; 25% tendinopathy, 62% Partial & 11% Full thickness tears https://t.co/Jw9rMUQBLs

RT @ericdeinMD #RNL26 Arthroplasty risks in RMD AxSpA - Respiratory complications (OR 1.7), PNA (2.2) SLE - complications ass w/ severity/activity. Renal failure, PE, sepsis, stroke, mortality depending on activity PsA - complications related to co-morbidities, not PsA https://t.co/jr0hwh3CPe

RT @ericdeinMD #RNL26 Inflammatory arthritis pts getting TKA: - increased risk of RBC transfusion (OR 1.39), infection (1.64) and readmission (1.46) - THA: also risk of mechanical complications (like dislocation) OR 1.3 https://t.co/ovW2C2EuXF

RT @RichardPAConway UIP pattern RA-ILD is where the big problem is. We are less good at treating this. Perhaps the newer agents such as nerandomilast will change this? #RNL26 https://t.co/Z0BXxyNrCI

RNL 26 Report: Spondyloarthritis Audrey Gibson, PA-C, reports from RheumNow Live 2026 in Dallas, Texas, about lectures presented during the "Staying Ahead of Spondyloarthritis" session. https://t.co/UjvauWoga5 https://t.co/Zv8dmUuVyD

Obesity, Surgery, and Optimizing Patient Care Rheumatologic care requires a multidisciplinary approach and collaboration with other specialties to treat complex systemic diseases. While many Pods at RheumNow Live are disease-specific, the Pod II focused on Advancing Practice on https://t.co/hvSY5yHZmd

The vasculitis session at #RNL26 was a fantastic update on inflamed blood vessels, large and small, by two experts in the field. https://t.co/KuVei8jiFu https://t.co/PR4h2qniEL

RT @RichardPAConway Comparative survival in incident RA-ILD 1955-1995 vs 1999-2014. We are getting better, althoug need to take into account the general survival improvement also. More work to do! #RNL26 https://t.co/VwV33tHgR8

RT @ericdeinMD #RNL26 @RheumNow Uzma Haque GLP1 on pts with  SLE and diabetes Retrospective study - major improvements in MACE HR 0.66 VTE HR 0.49 Renal progession HR 0.77 Mortality HR 0.26 A major tool for rheumatic care! https://t.co/qR3HKfsugZ